265
Participants
Start Date
October 19, 2022
Primary Completion Date
August 20, 2024
Study Completion Date
September 3, 2024
INV-202
INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
Placebo
Placebo Matching size and number of tablets
Clinica Integral del Paciente Diabético y Obeso, Mexico City
Northeast Clinical Research Center, Bethlehem
Endocrine and metabolic Consultants, Rockville
Physicians East, PA, Greenville
South Carolina Clinical Research LLC, Orangeburg
Endocrine Research Solutions, Inc., Roswell
ALL Medical Research, LLC, Cooper City
South Florida Research Institute, Lauderdale Lakes
Research Physicians Network Alliance, Boca Raton
Knoxville Kidney Center, Pllc, Knoxville
Centro de Investigación Médica y Reumatología S.C., Guadalajara
Cento de Investigacion Medica de Occidente, S.C., Guadalajara
Research by Design, LLC, Chicago
Clinical Research Consultants, LLC, Kansas City
North Texas Endocrine Center, Dallas
Biopharma Informatic, LLC, Houston
Linq Research, LLC, Pearland
Linq Research, LLC, Pearland
Clinical Advancement Center, PLLC, San Antonio
Palm Research Center, Inc, Las Vegas
National Institute of Clinical Research, Inc - Pomona, Pomona
North American Research Institute, San Dimas
National Institute of Clinical Research, Inc - Upland, Upland
Instituto Veracruzano en Investigacion Clínica S.C., Veracruz
National Institute of Clinical Research, Inc., Garden Grove
Central Coast Nephrology, Salinas
University of Vermont Medical Center, Burlington
Centre de recherche Clinique de Laval, Laval
GCP Research, Montreal
"Clinic- LJ, LTD", Kutaisi
LTD Clinic Rustavi, Rustavi
Aleksandre Aladashvili Clinic LLC, Tbilisi
Israel-Georgia Research Clinic Helsicore, LTD, Tbilisi
"LTD Adapt", Tbilisi
National Institute of Endocrinology, LTD,, Tbilisi
Diaverum Dialysis Centre of Baja and Nephrology Out-Patient Clinic of Baja St.Rokus Hospital, Baja
DPC Hospital - Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, 1st Department of Internal Medicine, Budapest
University of Debrecen, Debrecen
Flor Ferenc Hospital of Pest County, Kistarcsa
Medifarma-98 Kft, Nyíregyháza
Haemek medical center, Afula
Barzilai Medical Center, Ashkelon
Rambam Health Care Campus \ Rambam Medical Center, Haifa
Wolfson medical center, Holon
Hadassah Medical Center, Jerusalem
Meir Medical Center, Kfar Saba
Rabin Medical Center, Beilinson Campus, Petah Tikva
Ziv Medical Center - Endocrinology Clinic, Safed
Ziv Medical Center, Safed
Instituto de Diabetes Obesidad Y Nutricion , S.C., Cuernavaca
Cento de Investigacion Medica de Occidente, S.C., Guadalajara
Medical Office, Guadalajara
Unidad de Investigación Clinica y atencion Medica HEPA, Guadalajara
Investigación Médica, Mérida
St Lucas Clinical Research Center SA de CV, Mérida
Clinical Hospital Center Zemun, Belgrade
"General Hospital Vršac", Belgrade
University Clincial Center of Serbia, Belgrade
"University of Kragujevac - Klinicki Centar Kragujevac", Kragujevac
General Hospital Krusevac, Kruševac
University Clinical Center Nis, Clinic of Nephrology, Niš
University Clinical Center of Vojvodina, Novi Sad
Healt Center Uzice,General Hospital, Užice
Health Center Zajecar, Zaječar
L. Managadze National Center of Urology, LTD, Tbilisi
Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research, Tbilisi
Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Multi-center Clinical Trials, Tbilisi
Archangel St Michael Multiprofile Clinical Hospital Ltd, Tbilisi
"Ltd Institute of Clinical Cardiology", Tbilisi
Tbilisi Heart and Vascular Clinic LTD, Tbilisi
Georgian Dutch Hospital LLC, Tbilisi
LTD Tbilisi Heart Center, Tbilisi
Lead Sponsor
Collaborators (1)
Worldwide Clinical Trials
OTHER
Inversago Pharma Inc.
INDUSTRY